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MitochondriaUncoupling protein-2 (UCP2) is used by cells to control reactive oxygen species (ROS) production by mitochon-
dria. This ability depends on the glutathionylation state of UCP2. UCP2 is often overexpressed in drug resistant
cancer cells and therein controls cell ROS levels and limits drug toxicity. With our recent observation that
glutathionylation deactivates proton leak through UCP2, we decided to test if diamide, a glutathionylation cata-
lyst, can sensitize drug resistant cells to chemotherapeutic agents. Using drug sensitive HL-60 cells and the drug
resistant HL-60 subline, Mx2, we show that chemical induction of glutathionylation selectively deactivates pro-
ton leak through UCP2 in Mx2 cells. Chemical glutathionylation of UCP2 disables chemoresistance in the Mx2
cells. Exposure to 200 μM diamide led to a signiﬁcant increase in Mx2 cell death that was augmented when
cells were exposed to either menadione or the anthracycline doxorubicin. Diamide also sensitized Mx2
cells to a number of other chemotherapeutics. Proton leak throughUCP2 contributed signiﬁcantly to the energet-
ics of the Mx2 cells. Knockdown of UCP2 led to a signiﬁcant decrease in both resting and state 4 (i.e., proton
leak-dependent) respiration (~43% and 62%, respectively) in Mx2 cells. Similarly diamide inhibited proton
leak-dependent respiration by ~64%. In contrast, diamide had very little effect on proton leak in HL-60 cells. Col-
lectively, our observations indicate thatmanipulation of UCP2 glutathionylation status can serve as a therapeutic
strategy for cancer treatment.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Aerobic production of ATP is reliant on molecular oxygen (O2) and
the formation of an electrochemical potential (ΔΨm) across the mito-
chondrial inner membrane (MIM) [1]. In this process, electrons from
substrates are transferred through the respiratory complexes to O2 and
this is coupled to the efﬂux protons into the intermembrane space,
thus establishing the ΔΨm. This stored form of energy is then tapped
by ATP synthase to generate ATP, a process termed coupled respiration.
However, protons pumped into the intermembrane space can by-pass
ATP synthase and re-enter the matrix without generating ATP and this
is referred to as uncoupled respiration [2]. The Gibbs free energy stored
in ΔΨm is also used for the uptake of organic acids, cations/anions, and
proteins. Theuncouplingproteins (UCPs) are thought to translocate pro-
tons back into the matrix without coupling it to the co-import of other
molecules [3]. It is important to point out though that other reports
have shown that UCPs 1–3 transportmetabolites (e.g., lipid hydroperox-
ides) and calcium [4,5]. Whether or not these putative transport func-
tions require co-import of protons remains unclear. However, despiteeactive oxygen species; ΔΨm,
embrane
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tribute the ROS-quenching effects of UCPs to proton leak [6–8]. Indeed,
proton leak through the UCPs is biologically important. For instance,
proton leak through UCP1, which is exclusively expressed in brown
fat, is required for adaptive thermogenesis [9]. However, leak through
the other UCPs, UCP2 and UCP3, is not used for thermogenesis but to
control mitochondrial reactive oxygen species (ROS) emission [10]. A
higherΔΨm increases the likelihood that electronswill “spin-off”mainly
from complexes I and III and produce ROS [11,12]. For this reason, mito-
chondria are considered to be one of the main sources of cellular ROS.
The ability to control ROS through proton leak is considered the ﬁrst
line of defense against oxidative stress and is associated with increased
cell survival [13].
UCP2 plays important physiological roles ranging from control of
insulin release to satiety signaling and cell proliferation [14–16]. The abil-
ity of UCP2 to participate in somany physiological functions has been as-
sociated with its putative inducible proton leak mechanism, which in
turn affects ROS signaling cascades in a variety of cell types [2]. It has
been established that UCP2 proton leak diminishes mitochondrial ROS
production, which subsequently regulates signaling cascades [17,18].
Leak is dependent on ROS levels and reversible glutathionylation, a
posttranslational modiﬁcation involving the formation of a disulﬁde
between glutathione and a protein thiol [19,20]. Indeed, induction of
glutathionylation with diamide in thymocytes deactivates proton leak
in a UCP2-speciﬁc manner [19]. Further, ROS deglutathionylates UCP3,
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is easily reversed by diamide treatment [19]. Aside from its important
signaling functions, leak through UCP2 is required to keep ROS levels
in check. Loss of UCP2 function sensitizes cells to oxidative stress
[21,22]. Likewise, overexpression provides enhanced protection from
ROS-producing molecules [23]. Hence, UCP2 functions to control mito-
chondrial ROS emission through a proton leak mechanism.
Drug resistant cancer cells use many mechanisms to render che-
motherapeutic agents innocuous. One such mechanism is increased
UCP2 expression [24,25]. By increasing UCP2 expression, drug resistant
cancer cells increase proton leak which keeps cellular ROS levels within
tolerable limits, even when exposed to ROS-generating chemothera-
peutics [21,23,25–27]. Various cancer cell types, including breast cancer
cells, leukemia cells, human colon cancer cells, thyroid tumours, and
hepatomas, use UCP2 to fend off against the toxic effects of chemother-
apeutic agents [28–32]. With our recent observation that UCP2 is mod-
ulated by glutathionylation, we set out to determine if pharmacological
glutathionylation of UCP2 with diamide, a glutathionylation catalyst,
sensitizes drug resistant promyelocytic leukemia cells (HL-60/Mx2 or
Mx2) to chemotherapeutics. Unlike the drug sensitive parent line,
drug resistant Mx2 cells display higher rates of aerobic respiration,
fatty acid oxidation, and glucose metabolism [25,26]. Mx2 cells also
have normal cellular ROS levels and are highly resistant to the toxicity
of a broad range of chemotherapeutics [26,33]. These sharp deviations
in cell physiology are mostly attributed to the ampliﬁcation of UCP2
expression. Indeed, in comparison to other antioxidant proteins, UCP2
is heavily expressed in Mx2 cells, indicating the drug resistance of this
cell line is highly dependent on UCP2 [26]. Here we report that acute
treatment of Mx2 cells with diamide led to a robust decrease in UCP2-
dependent proton leak. This effect was absent in the drug sensitive
promyelocytic leukemia parent cell line (HL-60). The diamide-mediated
decrease in proton leak augmented the sensitivity of the Mx2 cells to a
number of different chemotherapeutic agents such as the anthracycline,
doxorubicin, and the ROS-generating menaquinone, menadione. Collec-
tively, our results show that targeted inhibition of UCP2 function by
glutathionylation can serve as a therapeutic approach to kill cancer cells.
2. Materials and methods
2.1. Cell lines and treatment
The drug sensitive human acute promyelocytic leukemia (APL)
suspension cell line HL-60 and drug resistant subline Mx2 were obtained
from American Type Culture Collection (ATCC, Manassas, VA). Authenti-
cation regarding sensitivity and resistance to chemotherapeutics was
performed by ATCC prior to shipping. The cells were routinely cultured
in high glucose Dulbecco's modiﬁed Eagle’s medium (DMEM containing
25 mMglucose, 4 mMglutamine, 1 mMpyruvate, Invitrogen, Burlington,
ON) supplemented with 20% (v/v) fetal bovine serum (FBS, Invitrogen,
Burlington, ON) and 2% (v/v) antibiotic–antimycotic (A.A., Invitrogen,
Burlington, ON). Every 2 days the media was changed and every 4 days
the cells were passaged and reseeded at 1×105 cells/mL in a ﬁnal volume
of 13 mL. Cells were grown for 4–5 days before each experiment. Cell
number and viability were determined using the trypan blue exclusion
assay. Cells were cultured for up to 15–20 passages, at which point
they were discarded. For diamide treatments, following 4 days of
growth, cells were treated with diamide (diluted in growth medium,
0–500 μM), incubated for 30 min at 37 °C, and used for experimenta-
tion. To test the effect of diamide on drug sensitivity, following diamide
treatment, cells were centrifuged at 200×g and then incubated for 24 h
in growth medium containing menadione (0–100 μM) or doxorubicin
hydrochloride (0–0.5 μM) [26].
For UCP2 knockdown, cells were grown for 2 days and then treat-
ed with Polybrene (2 μg/mL, Santa Cruz Biotechnologies) with either
UCP2 shRNA (shUCP2; Santa Cruz Biotechnologies) or scrambled
(control, shCtl; Santa Cruz Biotechnologies) shRNA lentiviral particles(5000 infectious viral particles (IFU)/mL, Santa Cruz Biotechnologies)
for 48 h. Cultures were then re-supplemented with fresh medium de-
void of lentiviral particles and Polybrene, and then incubated for an
additional 24 h in a medium including puromycin (1 μg/mL, Santa
Cruz). Transduced cells were then treated with diamide and isolated
for experimentation.
2.2. Cell survival assays
Cell survival was determined following diamide treatment using a
propidium iodide (PI) assay [26]. Cells were washed twice in washing
buffer (PBS+10 mM glucose) followed by a 10 min incubation in PI
(100 μg/mL, Sigma, St. Louis, MO) at room temperature. The PI solution
was then removed and cells were washed in washing buffer before
being placed in a 96-well plate in triplicates. Cells exposed to 5 mM
H2O2 served as the control. Excitation was measured at 485 nm and
emission at 645 nm using a microplate reader (SynergyMX, BioTek,
Winooski, VT). PI results were normalized to cell number.
2.3. Trypan blue exclusion assays
Trypan blue exclusion assays were conducted as described in [26].
An aliquot of the cell suspension was diluted in trypan blue solution
(Invitrogen, Burlington, Ontario) and cell viability was determined
using the Countess Cell Counter according to the manufacturer's in-
structions (Invitrogen, Burlington, ON).
2.4. Measurement of cellular ROS levels
2′,7′-Dichlorodihydroﬂuorescin diacetate (H2-DCFDA) was used
to measure total cellular ROS levels [26] and MitoSOX was used to
measure mitochondrial superoxide levels. For H2-DCFDA, following
diamide treatment, cells were centrifuged at 200×g for 5 min, washed
in 1 mLwashing buffer and then incubated in growthmedia containing
H2-DCFDA (20 μM). H2-DCFDA was removed and the sample was
washed twice in washing buffer before being placed in a 96-well plate
in triplicates. Cells exposed to 5 mM H2O2 served as the control. To
measuremitochondrial superoxide cellswere pre-loadedwithMitoSOX
(40 μM ﬁnal concentration, 10 min incubation) and then incubated
in diamide for an additional 30 min at 37 °C. Cells were then washed
twice in washing buffer before being placed in a 96-well plate in trip-
licates. Cells exposed to 1 mM paraquat (PQ; superoxide-producing
bipyridine molecule) served as the control. A 10 μL aliquot of the sample
was removed and cell number and viability were determined using the
trypan blue exclusion assay following diamide exposure for all assays.
Excitation was measured at 480 nm and emission at 528 nm for
H2-DCFDA and 510 nm/580 nm for MitoSOX using a microplate reader
(SynergyMX, BioTek, Winooski, VT). ROS levels were normalized to cell
number.
2.5. HPLC analysis of cellular glutathione pools
Glutathione quantiﬁcation was conducted as described in [34].
Cells treated with or without 200 μM diamide were washed in PBS
before being resuspended in 100 μL of 0.5% perchloric acid, vortexed,
and incubated on ice for 10 min. The resulting precipitate was removed
by centrifugation at 12000×g for 10 min at 4 °C. For GSH/GSSG deter-
minations, the supernatant was extracted and used. For determinations
of total glutathione associated with the proteome, the protein pellet
was resuspended in 100μL of 10 M sodium hydroxide and incubated
for 10 min at room temperature to hydrolyze thiol bonds between pro-
teins and glutathione. Samples were then centrifuged at 12000×g for
10 min at 4 °C and the supernatant was collected for analysis. Samples
were injected into an Agilent HPLC system equipped with a Pursuit C18
150×4.6 nm, 5 μL column (Agilent Technologies). The mobile phase
consisted of ddH2O+0.1% triﬂuoroacetic acid (TFA), pH 2.0: CH3OH
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1.0 mL/min and samples were run for 15 min each. Retention times of
reduced (GSH) and oxidized (GSSG) glutathione were conﬁrmed by
injecting known standards. GSH and GSSG were quantiﬁed using
Agilent Chemstation software. All values were normalized to cell pro-
tein content.
2.6. Measurement of oxygen consumption
Cells were counted and diluted to 13.3×106 cells for HL-60 and
3.3×106 cells for Mx2 and then treated with and without 200 μM di-
amide. Different amounts of cells were used since HL-60 cells are not
as aerobically active as Mx2 cells [25]. Following treatment, cells were
washed in washing buffer before being placed on ice. One milliliter of
reaction buffer (106 mM NaCl, 0.41 mM MgCl2, 25 mM Na2HPO4,
5 mM KCl, 10 mM glucose, pH 7.0) was pre-heated to 37 °C before
measurements were performed. Cell suspensions were then placed in
a temperature-regulated Clark-type electrode chamber (Oxytherm;
Hansatech Instruments Ltd, Norfolk England). Once resting respiration
was determined, state 4 respiration rates were assessed by injecting
oligomycin (ﬁnal concentration 10 μg/mL) into the electrode chamber.
Oxygen consumption was measured for 5–15 min at 37 °C. Oxygen
consumption was normalized to cell number.
2.7. Chemotherapeutics screen
Chemotherapeutic screens were performed using the Biolog assay
kit (PM-M14, Biolog, Hayward, CA) according to the manufacturer's
instructions. Cells treated with and without 200 μM diamide were
washed in washing buffer and then seeded at 4×104 cells/mL in
96-welled Biolog plates containing serum-free growth media. Cells
were incubated in the presence of the chemotherapeutic drugs for
24 h at 37 °C. Changes in cell viability were determined by adding
10μL of Redox Dye Mix B (Biolog, Hayward, CA) directly to each well.
Cells were then incubated for an additional 24 h. Absorbance was
measured at 590 nm using a microplate reader (SynergyMX, BioTek,
Winooski, VT).
2.8. BioGEE pulldown and immunoblot analysis
Glutathionylation state of UCP2 was tested as described in [19].
Cells were grown to 50% conﬂuency and then incubated for 1 h in
serum free DMEM containing 1 mM biotinylated glutathione ethyl
ester (BioGEE). Following the incubation, cells were isolated by centri-
fugation, washed once in washing buffer, and then lysed in RIPA buffer
containing 25 mM N-ethylmaleimide (NEM). Cell lysatewas then incu-
bated overnight at 4 °C under constant agitation in streptavidin beads
to elute BioGEE-tagged proteins. Beadswere ﬁrst isolated by centrifuga-
tion (200×g for 5 min) and the resulting pellet was washed once with
PBS. Note that the supernatant from the centrifugation (SN fraction)
was kept for immunoblot analysis. The beads were then treated with
4 M urea (in PBS pH 7.6) to dissociate BioGEE-tagged proteins from
the beads. The sample was then centrifuged to remove the beads and
the resulting supernatant (pull down fraction; PD) was kept for immu-
noblot analysis.
For immunoblot, sampleswere diluted to 1 mg/mL in Laemmli buff-
er and 30 μg of cell lysate was electrophoresed on a 12% isocratic
SDS-gel. For BioGEE samples, samples were diluted to 2–4 mg/mL and
60 μg of protein was loaded. Transfers to nitrocellulose membranes
were performed at room temperature at a voltage of 100 V. Following
blocking, membranes were incubated for 24 h at 4 °C with primary an-
tibodies directed against UCP2 (1/500, Abcam) or succinate dehydroge-
nase (SDH, 1/2000, Santa Cruz). For detection of UCP2 elution, Ponceau
staining of membranes served as the loading control. Membranes were
then incubated for 1 h at room temperature with the requisite horserad-
ish peroxidase-conjugated secondary antibody (anti-rabbit, anti-mouse,or anti-goat, 1/2000, Santa Cruz). Blots were visualized using enhanced
chemiluminescent substrate (ECL kit, Thermo Scientiﬁc).
2.9. Statistical analysis
Statistical analysis was performed using either paired one-tailed
Student's t test or one-way or two-way ANOVA with post-hoc Fisher
tests to determine statistical differences in means (Statview software,
SAS Institute Inc., USA). p≤0.05 was considered to be signiﬁcant. All
values were expressed as mean±SEM.
3. Results and discussion
3.1. Impact of diamide on HL-60 and Mx2 cell viability
The fact that many drug resistant cancer cells express high
amounts of UCP2 indicates that this protein could serve as a potential
target for enhancing the effectiveness of pharmaceuticals. Inhibition
of leak through UCP2 using genipin or the highly effective chromane
compound sensitizes drug resistant cells to chemotherapeutics
[21,26,27,35]. Overexpression of UCP2 on the other hand renders the
ROS-generating properties of the chemotherapeutic gemcitabine innoc-
uous [35].With our recent observations that UCP2 can be deactivated by
diamide-mediated glutathionylation, we set out to determine if induc-
tion of UCP2 glutathionylation with diamide sensitized drug resistant
cells to chemotherapeutics. First, we performed dose response analysis
to identify the appropriate concentration of diamide to use for our stud-
ies. Drug sensitiveHL-60 cells and thedrug resistantHL-60 subline,Mx2,
were exposed to different concentrations of diamide (0–500 μM) for
30 min and then tested for amount of cell death using propidium iodide
(PI). Cells were also exposed to 5 mMH2O2 for 30 min to induce maxi-
mum cell death. In HL-60 cells diamide treatment at all concentrations
did not increase PI ﬂuorescence relative to control (Fig. 1A). Mx2 cells
responded differently to diamide treatment. Exposure to 500 μM led
to an increase in cell death (Fig. 1A). Prolonged exposure to high con-
centrations of diamide is well known to induce cell death through the
activation of the mitochondrial permeability transition pore (MPTP)
which, once activated, depolarizes the MIM, thereby activating the
intrinsic apoptotic signaling cascade [36,37]. However, our group has
previously established a short incubation (10–60 min) with diamide
concentrations below 500 μM can be used to test glutathionylation
effects on metabolism without disrupting cell homeostasis [19,34].
Since glutathionylation deactivates UCP2, we decided to test if diamide
treatment altered total cellular ROS (H2-DCFDA) and mitochondrial
ROS (MitoSOX). H2-DCFDA assays revealed no changes in total cell
ROS levels in either the HL-60 or Mx2 cells (Fig. 1B). H2-DCFDA is
non-speciﬁc, can be reduced by redox active metals and molecules,
and can auto-catalyze ROS formation [38]. Further, leak through UCP2
is required to control mitochondrial ROS production and also protects
cancer cells from ROS-generating molecules [24]. Thus, we decided to
determine if diamide treatment speciﬁcally alters mitochondrial super-
oxide levels. Diamide treatment (0–500 μM) did not alter mitochondri-
al superoxide levels in HL-60 cells (Fig. 1C). Exposure of Mx2 cells to
200 μMdiamide led to a small but signiﬁcant increase in mitochondrial
superoxide levels (Fig. 1C). This increase is most likely associated with
the diamide-mediated glutathionylation of UCP2. Exposure to higher
amounts of diamide (500 μM) led to further increases in mitochondrial
superoxide. Mx2 cells also displayedmuch highermitochondrial super-
oxide levels than the drug-sensitive HL-60 cells.Mx2 cells do havemore
mitochondria and these drug resistant cells are more aerobically active,
whichmay account for the order ofmagnitudehighermitochondrial su-
peroxide [25]. The higher mitochondrial superoxide levels in Mx2 cells
could also explain why drug-resistant cells have higher levels of UCP2
protein. It is worthy to note that the remaining experiments were
conducted on cells exposed to 200 μMdiamide since this concentration
Fig. 1. Impact of diamide on HL-60 and Mx2 cell viability. Cells were exposed to diamide (0–500 μM) for 30 min and then tested for cell viability and cellular ROS levels. Exposure to
5 mM H2O2 or 1 mM PQ served as the control. (A) Diamide treatment increases Mx2 cell death. Following exposure to diamide, amount of cell death was measured by PI assay.
Fluorescence was corrected for cell number and expressed as a percent of control. (B) The increase in diamide-induced Mx2 cell death is not associated with changes in total
cell ROS levels. Amount of cell ROS was measured using H2-DCFDA. (C) Diamide treatment increases mitochondrial superoxide levels in Mx2 cells but not HL-60 cells. Superoxide
levels were measured using MitoSOX. All values were normalized to cell number. n=4, 1-way ANOVAwith post-hoc Fisher test. * corresponds to p≤0.05, ** corresponds to p≤0.01.
Statistical signiﬁcance was determined by comparing treated cells to control cells.
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levels in Mx2 cells.
3.2. Effect of diamide on cellular glutathione pools
Diamide is known to alter or deplete cell glutathione, which could
account for the increased amount of Mx2 cell death [39]. Indeed, sur-
vival of drug resistant cells depends to a large extent on the ROS
quenching and xenobiotic eliminating capabilities of glutathione.
Hence, we decided to measure the absolute levels of reduced and ox-
idized forms of glutathione (GSH and GSSG, respectively), as well as
the GSH/GSSG ratio and the amount of glutathione associated with
the cellular proteome. GSH is the dominant form of glutathione in the
cell. This is maintained by a balance between reduction of GSSG back
to GSH following ROS quenching and glutathione biosynthesis path-
ways [40]. However, in cancer cells the glutathione pool can range
from highly reduced to extremely oxidized and this is dependent on tis-
sue environment, nutrient status, O2 availability, and the amount of ROS
being produced. For instance, drug resistant cells and advanced cancers
can have a highly oxidized glutathione pool which may be the result of
ROS sequestration [41,42]. Absolute GSH levels were signiﬁcantly lowerin Mx2 cells in comparison to their drug sensitive counterpart (Fig. 2A).
On the other hand GSSG levels were higher in Mx2 cells, indicating an
increased propensity to oxidize GSH to GSSG. There was no observable
difference in the total amount of free glutathione (GSH+GSSG) be-
tween the HL-60 and Mx2 cells, indicating no increase in glutathione
biosynthesis in the drug resistant cells. Using the absolute GSH and
GSSG levels, we also calculated the relative GSH/GSSG in HL-60 and
Mx2 cells. The redox state of the GSH/GSSG pair can have a profound
impact on cellular physiology and is highly variable in cancer cells.
GSH/GSSG was more reduced in HL-60 than Mx2 cells (~25 vs. ~10)
(Fig. 2A). Kawiak et al. previously showed that the GSH/GSSG is more
oxidized inMx2 cells [42]. However, in that study the authors calculated
the GSH/GSSG in HL-60 and Mx2 cells to be ~12 and ~10, respectively.
We also measured the total amount of glutathione associated with the
cellular proteome. GSH can conjugate to available protein thiols forming
protein glutathionemixed disulﬁdes, a process called glutathionylation.
Glutathionylation is a tightly regulated process and is enzymatically
mediated mostly by glutaredoxins (Grx), and to a lesser extent
sulﬁredoxins and glutathione S-transferases [20]. However, a highly
oxidized GSH/GSSG can lead to the spontaneous glutathionylation of
proteins [43]. Non-speciﬁc glutathionylation reactions are associated
Fig. 2.Measurement of glutathione pools in HL-60 and Mx2 cells treated or untreated with diamide. Cells were incubated for 30 min in the presence or absence of 200 μM diamide.
Gluathione was then extracted and the amount of GSH and GSSG was analyzed by HPLC. The GSH/GSSG was calculated based on the absolute GSH and GSSG levels. The amount of
glutathione associated with cellular protein was also examined (see Materials and methods). (A) Mx2 cells have a more oxidized glutathione pool and have more protein glutathione
mixed disulﬁdes than HL-60 cells not treated with diamide. (B) Measurement of cellular glutathione and protein glutathione mixed disulﬁdes in HL-60 and Mx2 cells treated with di-
amide. n=3, Student's t test. * corresponds to p≤0.05, ** corresponds to p≤0.01.
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ders, and cancer [44]. Mx2 cells had more glutathione associated with
the proteome than HL-60 cells (Fig. 2A).
Pre-treatment of HL-60 andMx2 cells with 200 μMdiamide induced
a decrease in the absolute levels of GSH and GSSG (Fig. 2B). However,
GSH and GSSG levels were signiﬁcantly lower and higher, respectively,
in Mx2 cells. While GSH/GSSG was still more oxidized in Mx2 cells, di-
amide (a glutathionylation catalyst) did not alter GSH/GSSG in either
cell type (Fig. 2B). Intriguingly, diamide treatment did not cause detect-
able increases overall in the amount of glutathioneprotein conjugates. It
is important to point out that concentrations of diamide around 100–
200 μM do not induce hyper-glutathionylation [19]. Higher amounts
(≥500 μM) are required to induce overt increases in the total amount
of protein-glutathione adducts. This could account for the lack of total
change in the glutathionylation state of proteins in each cell type. The
amount of glutathione associated with cell protein was, however, still
signiﬁcantly higher in Mx2 cells (Fig. 2B). As expected though, diamide
did partially deplete cell glutathione (both GSH and GSSG) in both
HL-60 and Mx2 cells. Thus, diamide-mediated depletion of glutathione
can be excluded as the reason forMx2 cell death. Hence, we can conclude
that Mx2 cells have a more oxidized glutathione pool and a more
glutathionylated proteome. It is important to point out that cellular GSH
concentration ranges from 5 to 10 mM. In our study diamide depleted
GSH by ~50%, which would still leave mM amounts of GSH in the cell
andwould still be enough to quench ROS or detoxify xenobiotics. In addi-
tion, depletion of cell glutathione with butathione sulfoximine does not
increase baseline cell ROS levels [19]. Moreover, the diamide-mediated
increase inMx2 cell deathwas not due to interferencewith cellular gluta-
thione pools and is thus most likely associated with alterations in the
glutathionylation of speciﬁc proteins.
3.3. Diamide treatment inhibits proton leak in Mx2 cells only
Given that UCP2 is highly expressed in drug resistant cancer cells, we
set out to determine if diamide can inhibit proton leak inMx2 cells. HL-60
and Mx2 cells were pre-treated with or without diamide for 30 min and
then tested for O2 consumption under resting and oligomycin-induced
state 4 (proton leak or non-phosphorylating) respiratory conditions. Toensure total deactivation of ATP synthase, we used saturating amounts
of oligomycin (10 μg/mL). Following diamide treatment, a trend for an
increase in resting respiration was observed in the HL-60 cells; howev-
er, this did not reach signiﬁcance (Fig. 3A). Diamide had no impact on
oligomycin-induced state 4 respiration (Fig. 3A). A trend for increased
resting respirationwas also observed in theMx2 cells (Fig. 3B). Howev-
er, diamide treatment did induce a signiﬁcant decrease in proton
leak-dependent respiration in the Mx2 cells (Fig. 3B). In fact, diamide
pre-treatment decreased leak by ~64% in Mx2 cells. It is important to
point out that Mx2 cells also had higher resting O2 consumption rates
than their drug sensitive counterpart (~80% higher). This observation
is consistent with our previous work showing that Mx2 cells are more
aerobically active than HL-60 cells [25,26]. In contrast, leak was not af-
fected in the drug sensitive HL-60 cells. The trend for an increase in rest-
ing respiration following diamide treatment prompted us to test the
effect of higher diamide concentrations on resting respiration in
HL-60 and Mx2 cells. Resting respiration tended to increase following
titration of diamide up to 200 μM but this did not reach signiﬁcance
(Fig. 3C). Further increases in diamide (500 μM and 800 μM) led to a
progressive suppression of respiration in both HL-60 and Mx2 cells
(Fig. 3C). Diamide at low concentrations is known to stimulate respira-
tion in certain cell types but in our case 200 μMdiamide did not lead to
a signiﬁcant increase in respiration [45].
We next tested the glutathionylation state of UCP2. HL-60 and Mx2
cells were treated with biotinylated glutathione ethyl ester (BioGEE),
which tags vacant glutathionylation sites on proteins with biotin. A
more deglutathionylated protein will bind more BioGEE providing an
index for protein glutathionylation state. More BioGEE-tagged UCP2
was eluted from Mx2 than HL-60 cells (Fig. 3D). It is important to re-
member thatMx2 cells overexpress UCP2 and rely on UCP2 tomaintain
low cell ROS levels even when exposed to pharmacological agents that
induce oxidative stress [26].
3.4. Diamide effect on proton leak respiration in Mx2 cells is due to
inhibition of UCP2
Our observation that diamide inhibits proton leak in Mx2 cells
prompted us to determine if this was due to UCP2. We subsequently
Fig. 3. Diamide selectively decreases proton leak-dependent respiration in drug resistant Mx2. Cells were exposed to 200 μM diamide and then tested for oxygen consumption
under resting and state 4 conditions. Following the measurement of resting respiration, cells were treated with oligomycin (10 μg/mL) to induce state 4 respiratory conditions.
(A) Resting and oligomycin-induced state 4 respiration in HL-60 cells. (B) Resting and oligomycin-induced state 4 respiration in Mx2 cells. n=4, Student's t test. * corresponds
to p≤0.05. (C) Impact of diamide titration of resting respiration rates in HL-60 and Mx2 cells. Following the establishment of resting respiration rates diamide was titrated from
100 to 800 μM in the Clark-type electrode chamber. After diamide addition, rates were measured for up to 5 min. n=4, 1-way ANOVA with post-hoc Fisher test. * corresponds
to p≤0.05, ** corresponds to p≤0.01. (D) Assessment of amount of glutathionylated UCP2 in HL-60 (H) and Mx2 (M) cells. Cells were treated with BioGEE, lysed, and then
UCP2 was eluted using streptavidin beads. The amount of eluted UCP2 (pull down; PD) was detected by immunoblot. Loading input corresponds to the total amount of cell lysate
used for UCP2 elution. Note that 60 μg of protein was used in the electrophoresis.
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lentiviral particles to knockdown UCP2 expression. Scrambled RNA
served as the control. Transduction with shUCP2 led to ~76% and
~67% decrease in UCP2 protein levels in HL-60 and Mx2 (Fig. 4A).
Next, we tested if knockdown of UCP2 in either cell type had any im-
pact on resting or oligomycin-induced state 4 respiration and if the
decreased amount of UCP2 abolished the diamide effect in the Mx2
cells. As shown in Fig. 4B, knockdown of UCP2 did not induce any
changes in resting respiration in HL-60 cells. However, knockdown
of UCP2 did induce a small decrease in oligomycin-induced (state 4;
leak dependent) respiration (Fig. 4B). Pre-treatment with diamide
had no effect on resting or oligomycin-induced respiration in HL-60
cells knocked-down for UCP2 (Fig. 4B). In contrast, knockdown of
UCP2 in Mx2 cells induced a signiﬁcant decrease in both resting and
oligomycin-induced respiration (Fig. 4C). Moreover, knockdown of
UCP2 abolished the diamide-mediated inhibition of this proton leak
respiration in the Mx2 cells. It is also important to note that treatment
of control Mx2 cells with diamide lowered proton leak to the same
level as cells knocked down for UCP2. These results not only conﬁrm
that UCP2 plays a central role in mitochondrial energetics in drug re-
sistant cells but that its activity can be suppressed with diamide. We
also observed that UCP2 plays a small energetic role of drug sensitiveHL-60 cells. However, UCP2 could not be inhibited in these cells by di-
amide. This could simply be due to the fact that HL-60 cells contain
less UCP2 protein.
3.5. Diamide exposure sensitizes drug resistant Mx2 cells
to chemotherapeutics
Mitochondria are now emerging as important targets for cancer
treatment. For example, the chemotherapeutic cisplatin is known to
induce its toxic effects by enhancing mitochondrial ROS production
and inducing mitochondrial damage [21]. Proton leak through UCP2 or
chemical induction of proton leak with protonophore FCCP mitigates
these effects [21]. The targeted inhibition of UCP2with drugs and natural
products sensitizes drug resistant cancer cells to chemical agents [26,27].
Our observation that diamide acts as an inhibitor of UCP2 in drug resis-
tant cells prompted us to decipher if this glutathionylation catalyst can
sensitize the drug resistant Mx2 cells to chemotherapeutics. To do this,
we employed the Biolog assay kit, which allows one to test the effects
of a wide breadth of anti-cancer agents on cell status. Prior to the
assay, HL-60 and Mx2 cells were pre-treated with or without 200 μM
diamide (Fig. 5). Diamide pre-treatment sensitized HL-60 cells to two
chemotherapeutic agents, namely, 4′-demethyl epipodophyllotoxin and
Fig. 4. Diamide inhibits leak through UCP2 speciﬁcally in Mx2 cells. HL-60 (H) and Mx2 (M) cells were treated with scrambled shRNA (control; shCtl) or shUCP2 lentiviral particles
to knockdown UCP2. (A) Detection of UCP2 in cells treated with shCtl and shUCP2. (B) Resting and oligomycin-induced state 4 respiration in HL-60 cells treated or untreated with
200 μM diamide. (C) Resting and oligomycin-induced state 4 respiration in HL-60 cells treated or untreated with 200 μM diamide. n=4, 2-way ANOVA with Fisher's post-hoc
test. * corresponds to p≤0.05, ** corresponds to p≤0.01, shCtl vs. shUCP2. ## corresponds to p≤0.01,−diamide vs. +diamide.
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Mx2 cells to six different chemotherapeutic agents including 4′-demethyl
epipodophyllotoxin, Podoﬁlox, all-trans-retinoic acid,mitomycin C, doxo-
rubicin hydrochloride, and quercetin dihydrate (Fig. 5). It is interesting to
note that diamide sensitized both HL-60 and Mx2 cells to 4′-demethyl
epipodophyllotoxin which is a chemical analog of etoposide. Also, di-
amide sensitized Mx2 cells to doxorubicin but not daunorubicin which
are both classiﬁed as anthracyclines. Although drugs have different sites
of action, they can all induce oxidative stress through ROS production.
This could be related to auto-catalysis of ROS production or the induction
of ROS genesis bymitochondria (e.g., through inhibition of the respiratory
chain). For instance, all-trans-retinoic acid is known to induce ROS pro-
duction [46]. Anthracyclines are able to auto-catalyze superoxide for-
mation by cycling between oxidized and semi-reduced states [47]. The
difference between doxorubicin and daunorubicin may be related to
their ROS-generating properties. We had previously established that
Mx2 cells havemuch lower levels of ROS in the presence of doxorubicin
when compared to HL-60 cells. This difference was attributed to UCP2
function since inhibition of proton leak increased ROS levels and in-
duced oxidative stress in Mx2 cells [26].
Our results from theBiolog assay indicate that diamide treatment sen-
sitizes Mx2 cells to a variety of chemotherapeutics. The Biolog assay is
based on the ability of cells to reduce a “redox dye” to a colored product
that is detected spectrophotometrically. Reduction of the dye is reliant on
the NADH generated by normal metabolic processes. As NADH levels are
dependent on both production and consumption processes, it is not a
direct measure of cell viability. Further, redox dyes like tetrazoliums can
also react with NADPH which also increases in production when cellsare exposed to ROS or ROS-generating drugs and molecules [48,49]. We
thus decided to perform cell death and viability assays on diamide-
treated cells exposed to eithermenadione or doxorubicin.We ﬁrst tested
if diamide-mediated inhibition sensitizes Mx2 cells to menadione, a
naphthoquinone that produces superoxide. We had previously shown
that UCP2 inhibition with genipin sensitizes Mx2 cells to menadione
treatment [26]. Exposure of HL-60 cells to menadione (50 and 100 μM)
for 24 h led to a robust increase in the amount of cell death (Fig. 6A). Di-
amide pre-treatment did not augment the toxicity of menadione in the
HL-60 cells. In contrast, menadione did not induce any changes in Mx2
cell viability. However, co-treatment ofMx2 cells with diamide andmen-
adione (50 and 100 μM) led to an increase in cell death (Fig. 6A).Wenext
tested if diamide also increases the killing effect of doxorubicin. As shown
in Fig. 6B, diamide did not enhance the toxicity of doxorubicin in HL-60
cells. On the other hand, diamide was able to increase the amount of
Mx2 cell death following treatment with 0.1 and 0.5 μM doxorubicin
(Fig. 6B). We then conﬁrmed these observations by measuring the num-
ber of live cells using trypan blue. In the absence of diamide, menadione
(50 and 100 μM) and doxorubicin (0.1 and 0.5 μM) reduced the number
of live HL-60 cells in culture by ~50–60% (Fig. 7A and B). As expected,
Mx2 cells displayed resistance to both menadione and doxorubicin
treatment. Indeed, menadione treatment (50 and 100 μM) only re-
duced the number of live Mx2 cells by ~15%, whereas doxorubicin re-
duced live cell number by ~10% (0.5 μM) (Fig. 7A and B). However,
diamide pretreatment enhanced the toxicity ofmenadione and doxoru-
bicin in Mx2 but not HL-60 cells (Fig. 7A and B). This result would sug-
gest that diamide disables the resistance of Mx2 cells to toxic agents.
These observations are in full agreement with our previous work that
Fig. 5. Diamide treatment sensitizes Mx2 cells to various chemotherapeutics. Cells were treated or untreated with diamide (200 μM). Sensitivity to chemotherapeutics was tested
using the Biolog assay (see Materials and methods). n=4, Student's t test. * corresponds to p≤0.05.
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cells to anthracycline treatment [26]. Diamide pretreatment ampliﬁes
drug toxicity in Mx2 by deactivating proton leak through UCP2. This is
achieved by the glutathionylation of UCP2. We have previously shown
that the glutathionylation catalyst diamide deactivates leak through
UCP2 by conjugating glutathione to exposed thiol residues [19]. Further,
HL-60 cells do not express UCP2 in abundance unlike their drug resistant
counterparts which use UCP2 to disable drug toxicity. Hence, diamide
enhances drug toxicity by glutathionylating UCP2 in Mx2 cells.
Redox circuits are increasingly recognized as important in the
modulation of protein function. To this end, glutathionylation serves a
regulatory arm of redox signaling, modulating protein function through
disulﬁde bridge formation between protein thiols and glutathione [50].
Glutathionylation is a highly regulated protein-speciﬁcmechanism that
can however become deregulated under pathological conditions. In-
deed, alterations in protein glutathionylation are associatedwith differ-
ent cancer phenotypes and have been shown to play a role in drug
resistance [51]. In this study, we showed that diamide-induced chemi-
cal glutathionylation of UCP2 in drug resistantMx2 cells not only inhibits
proton leak but sensitizes these cells to chemotherapeutics. Although
diamide did reduce the amount of free glutathione in HL-60 and Mx2cells, the diamide effects in Mx2 cells are attributed to UCP2 inhibition
of proton leak by glutathionylation. These observations were conﬁrmed
by knocking down UCP2 in Mx2 cells and cross examining these effects
using the drug sensitive parental HL-60 cell line. Manipulations in
redox environment and the use of antioxidants have been considered
as therapeutic strategies for cancer treatment [52,53]. However, such
approaches do not work for all cancers, due to extreme variability in
redox environment [54]. Here we have provided ﬁndings that could be
exploited in the development of new approaches for the treatment of
cancer. Further research is required to determinewhether or notmanip-
ulation of glutathionylation can effectively be used in cancer cytotoxic
strategies. Moreover a greater fundamental understanding of protein
glutathionylation in oncology is necessary. However our ﬁndings indi-
cate that the induction of UCP2 glutathionylation may serve as another
tool in the eradication of cancer.
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Fig. 7.Measurement of amount of live cells by trypan blue exclusion assay. (A) Impact of diamide onmenadione toxicity. HL-60 andMx2 cells were treated or untreatedwith diamide for
30 min and then incubated for 24 h with menadione (0–100 μM). (B) Effect of diamide on doxorubicin toxicity. HL-60 andMx2 cells were treated or untreated with diamide for 30 min
and then incubated for 24 h in doxorubicin (0–0.5 μM). n=4, 1-way ANOVA with Fisher's post-hoc test. * corresponds to p≤0.05, ** corresponds to p≤0.01.
Fig. 6.Measurement of amount of cell death by PI assay. (A) Impact of diamide on menadione toxicity. HL-60 and Mx2 cells were treated or untreated with diamide for 30 min and
then incubated for 24 h with menadione (0–100 μM). (B) Effect of diamide on doxorubicin toxicity. HL-60 and Mx2 cells were treated or untreated with diamide for 30 min and
then incubated for 24 h in doxorubicin (0–0.5 μM). n=4, 1-way ANOVA with Fisher's post-hoc test. * corresponds to p≤0.05, ** corresponds to p≤0.01.
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